12:00 AM
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lower dose submicron diclofenac: Phase III data

A double-blind Phase III trial in 305 patients aged 41-90 with OA of the hip or knee showed that thrice-daily 35 mg submicron diclofenac met the primary endpoint of reducing mean WOMAC pain subscale scores from baseline to week 12 vs. placebo (44.1 vs. 32.5 point reduction, p=0.0024). The twice-daily 35...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >